Related Experiment Video

Updated: Oct 2, 2026

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

[Pharmacokinetic elements of sodium valproate. Use in febrile convulsions in children]

F Perignon, M A Novella-Pequinot, P Beaune

    Archives Francaises De Pediatrie
    |January 1, 1983
    PubMed

    Insights

    This study examined sodium valproate (DPA) pharmacokinetics in infants after febrile seizures. Plasma DPA levels were not dose-dependent in prolonged treatment, and hepatic toxicity risks should be weighed against seizure prognosis.

    Area of Science:

    • Pharmacology
    • Pediatrics
    • Neurology

    Context:

    • Febrile convulsions are common in infants.
    • Sodium valproate (DPA) is used to treat seizures.
    • Understanding DPA pharmacokinetics is crucial for pediatric treatment.

    Purpose:

    • To investigate the pharmacokinetic profile of sodium valproate in children following a febrile convulsion.
    • To assess the relationship between DPA dosage and plasma concentrations during prolonged treatment.
    • To inform clinical decisions regarding DPA use in pediatric febrile convulsions.

    Summary:

    • A single oral dose of 20 mg/kg sodium valproate in infants yielded specific pharmacokinetic parameters: T max 2.4 hr, C max 94 µg/ml, T 1/2 12.4 hr, Vd 0.25 L/kg, and CL 0.014 L/kg/hr.
    • Prolonged treatment analysis indicated no correlation between daily dosage and measured plasma DPA concentrations.
    • The study highlights the need to balance DPA's potential hepatic toxicity against the generally favorable prognosis of febrile convulsions.

    Impact:

    • Provides essential pharmacokinetic data for sodium valproate in pediatric populations.
    • Suggests that plasma DPA levels may not be directly proportional to dosage in prolonged therapy.
    • Emphasizes careful consideration of DPA's safety profile in the context of febrile convulsion management.

    More Related Videos

    Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings10:46

    Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

    Published on: September 1, 2023

    Seizure Activity Induced by Electroshock in Drosophila Larvae06:10

    Seizure Activity Induced by Electroshock in Drosophila Larvae

    Published on: June 6, 2025

    Related Concept Videos

    Antiepileptic Drugs: Sodium Channel Blockers01:08

    Antiepileptic Drugs: Sodium Channel Blockers

    Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
    Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
    Among the most commonly prescribed antiepileptic drugs are...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...